Embed Size (px)
Citation preview
The public benefits of health and The public benefits of health and medical researchmedical research
Professor Warwick Anderson
Chief Executive Officer
NHMRC Act amended 2006Establishes NHMRC as an independent statutory agency within the health portfolio(a) To raise the standard of individual and public health throughout Australia(b) To foster the development of consistent health standards between the various States and Territories(c) To foster medical research and training and public health research and training throughout Australia;
and(d) To foster consideration of ethical issues relating to health
NHMRC’s Strategic Plan - ParliamentMust contain “the CEO’s assessment of the major national health issues that are likely to arise during the
period (of the Strategic Plan)”.
“Highways to Health”
PreventionImproved delivery
of primary, hospital health
care
PROSPERITY
Improving health
globally and regionally
KNOWLEDGE
RESEARCH
New treatments, therapies
IMPROVED INDIVDUAL AND COMMUNITY HEALTH
Innovative industry
development
NHMRC Funding Schemes - NHMRC Funding Schemes - SummarySummary
Support for health and medical Research – •Program Grants•Project Grants •Development awards
Building Australia's Research capacity•People:
•Fellowships• Career Development Awards• Training Fellowships • Scholarships
•Fields•Capacity Building Grants in Population health Research•Capacity Building Grants in Health services Research•Centres of Clinical Research Excellence
•Research Infrastructure:• Infrastructure Grants for Independent Medical Research Institutes• Enabling Grants• Equipment Grants
Grant $ Number
Program Grants $103,319,442 65Project Grants $281,747,558 1719Development Grants $3,084,852 36Priority & Strategic Grants $7,471,287 25
Grants for support of research
27%21%21%22%22%23%23%30%
48%42%
40%36%34%34%36%37%
37%
39%42%43%41%33%
44%
25%
0
400
800
1200
1600
2000
2400
2800
3200
2000 2001 2002 2003 2004 2005 2006 2007
Year of Application
Num
ber o
f app
licat
ions
NHMRC Project GrantsNHMRC Project GrantsMore could be fundedMore could be funded
Fundable, but not funded (score ≥4)
Funded
Not recommended for funding (score <4)
NHMRC research expenditure in 2007
Where the Funding GoesWhere the Funding GoesAdministering InstitutionAdministering Institution
NHMRC Funding to all NHMRC Funding to all Universities (2000 and 2007)Universities (2000 and 2007)
$0
$10,000,000
$20,000,000
$30,000,000
$40,000,000
$50,000,000
$60,000,000
$70,000,000
$80,000,000
Univers
ity of
Melb
ourne
Univers
ity of
Syd
ney
Monas
h Univ
ersity
Univers
ity of
Que
ensla
nd
Univers
ity of
Wes
tern A
ustra
lia
Univers
ity of
New
Sou
th W
ales
Univers
ity of
Ade
laide
Austra
lian N
ation
al Univ
ersity
Univers
ity of
New
castl
e
Flinde
rs Univ
ersity
La Trob
e Univ
ersit
y
Queen
sland
Univ
ersity
of Tec
hnolo
gy
Griffith
Univ
ersity
Curtin
Univers
ity of
Techn
ology
Univers
ity of
Sou
th Aus
tralia
James
Coo
k Univ
ersity
Deakin
Univ
ersity
Univers
ity of
Techn
ology
Syd
ney
Murdo
ch U
nivers
ity
Univers
ity of
Tasman
ia
Univers
ity of
Woll
ongo
ng
Macqu
arie U
nivers
ity
Edith C
owan
Univ
ersity
Univers
ity of
Ball
arat
Swinburn
e Univ
ersity
Univers
ity of
Can
berra
Centra
l Que
ensla
nd U
nivers
ity (C
QU)
Austra
lian C
atholi
c Univ
ersity
Vic
Charle
s Darw
in Univ
ersity
Victori
a Univ
ersity
of Tec
hnolo
gy
Univers
ity of
New
Eng
land
Charle
s Stur
t Univ
ersity
Univers
ity of
Wes
tern S
ydne
y
Univers
ity of
Sou
thern
Queen
sland
20002007
NHMRC Funding of top 10 NHMRC Funding of top 10
Institutions - Institutions - 20082008
0
10
20
30
40
50
60
70
80
Uni
Mel
bour
ne Uni
Sydn
ey
Mon
ash UQ
QIM
R
UNSW
Bake
rHe
art
Inst
itute
Uni
Adel
aide UW
A
Wal
ter
and
Eliza
Hall
Inst
itute
Fund
s ($
m)
Top 10 = 66.9% of total funds
Percentage of NHMRC research expenditure to each state and territory 2000 – 2007
Where the Funding Where the Funding GoesGoes
“Highways to Health”
PreventionImproved delivery
of primary, hospital health
care
PROSPERITY
Improving health
globally and regionally
KNOWLEDGE
RESEARCH
New treatments, therapies
IMPROVED INDIVDUAL AND COMMUNITY HEALTH
Innovative industry
development
$0
$30
$60
$90
$120
$150
2000 2001 2002 2003 2004 2005 2006 2007
Mill
ions Asthma*
Arthritis andOsteoporosis*
Cancer *
CardiovascularDisease*
Diabetes*
Injury
Mental Health #
National Health National Health Priority Areas (NHPA)Priority Areas (NHPA)
• NHMRC has a target of allocating 5% of the Medical Research Endowment Account (MREA) to Aboriginal and Torres Strait Islander related research
Aboriginal & Torres Aboriginal & Torres Strait Islander ResearchStrait Islander Research
NHMRC Funding for NHMRC Funding for Indigenous Health Funding Indigenous Health Funding
(2000-2007)(2000-2007)
$0
$5,000,000
$10,000,000
$15,000,000
$20,000,000
$25,000,000
$30,000,000
2000 2001 2002 2003 2004 2005 2006 2007
Patents in NHMRC project grant applications (2000 – 2006)
Intellectual PropertyIntellectual Property
A Study of NHMRC A Study of NHMRC final reportsfinal reports
• 1208 final reports from grants that ended in 2003, 2004 and 2005
• With a total value of $460.1 million of NHMRC funding between 1998 and 2005.
• Scholarships, equipment grants and block funding are excluded.
The following slides are an analysis of data received on final reports from NHMRC funded grants. This includes:
Has this research award resulted in the development of Intellectual Property?
Yes 227 19%No 953 79%Not Answered 28 2%Total 1208 100%
Intellectual PropertyIntellectual Property
19%
79%
2%
CommercialisationCommercialisationReported commercial actions arising out of the research includes 29 start up companies, 11 reports of sales of products, and 3 IPO listings.
Commercial Potential Type End year 2003 End year 2004 End year 2005 Grand Total
Patents assigned or licenced 6 26 25 57
Interest from commercial party 4 17 28 49
Development of therapeutic value 2 21 22 45
Start up company formed 2 14 13 29
Interest from the institutions commercial arm 1 11 16 28
Joint ventures with commercial interests 1 11 8 20
Successful clinical trials 0 5 6 11
Development of Scientific Services 0 6 4 10
Sales in products and therapies 0 3 4 7
Revenue generated from royalties 1 3 0 4
IPO Listing 0 1 2 3
Licence options converted 0 2 0 2
Total investment of $460.1 million for 1208 NHMRC grants resulted in leveraged funds of $254.4 million from;
• National sources: $124.1 million
• International sources: $130.3 million
Leverage of National and Leverage of National and International fundsInternational funds
Leverage of National and Leverage of National and International fundsInternational funds
$US31.1 million (10% of total NIH international investment)
New policy and practice focusedNew policy and practice focusedresearch: NHMRC Partnershipsresearch: NHMRC Partnerships
NHMRC Partnerships will focus on informing both policy and practice inhealth. This represents a new focus for the NHMRC in 2008.
The initiative will:• help create partnerships between policy makers, managers, clinicians and
researchers• provide funding and support to create new opportunities for researchers and• policy makers to work together
The aims are to:• Lead to more effective connections between policy makers and researchers• Improve the availability and quality of research evidence to inform policy• Process
NHMRC Partnerships will initially fund two types of awards• NHMRC Partnership Projects (ARC Linkage -like)• NHMRC Partnerships Centres for Research excellence
2005 Nobel Prize WinnersProfessor Barry MarshallProfessor Robin Warren
University of Western Australia
Marshall and Warren shared the Nobel Prize in Physiology or Medicine for their discovery of the Helicobacter pylori and its role in gastritis and peptic ulcer disease.
1996 Nobel Prize WinnerProfessor Peter Doherty
John Curtin School of Medical Research
Professor Doherty received the Nobel Prize for his milestone research into cellular immunology and discovery of how the body's immune system recognises virus-infected cells.
University of Queensland
Honoured as “Australian of the Year” for his groundbreaking work on the development of a vaccine for cervical cancer.
His work will prevent a virus that leads to half a million cases of cancer in women around the world each year, and takes hundreds of thousands of lives.
2006 Australian of the YearProfessor Ian Frazer
NHMRC support :• Development Grants (under review)• Support Enhancement Options
• Australian success stories: – Cochlear - Total revenue for the year 2006 increased
30% to a record $452.3 million– ResMed - Delivered a record financial performance
achieving $607 million in revenues, an increase of 43% from 2005
– CSL (now with Gardasil!) - Consolidated Group profit for 2007 $539.3 million
Commercial outcomesCommercial outcomes
• Australia’s main public health strategy in reducing the prevalence of dental caries.
• NHMRC has funded evaluative research since the 1980s (validating the safety, optimal levels and cost-effectiveness of water fluoridation)
• For each $1 invested in water fluoridation, estimated savings in dental treatment range from $12.60 to $80.00, with the greatest benefit to the most disadvantaged.
• NHMRC supported research has:– informed public debate, – provided an objective view on costs and benefits, and – provided reports that enable politically challenging policy decisions.
Water Fluoridation
Source: Access Economics, draft Report – Returns to NHMRC funded R&D (2008)
• It is estimated that, in 2008, there will be:– 14,700 hospitalisations– 5,285 deaths
• VET costs $116,970 per case due to lost productivity from premature death.
• Health system expenditure is $10,007 per case.
• NICS developed and implemented the Stop the Clot campaign.
• Savings from the NHMRC component alone would be 5 lives per annum and $1.6 million in savings to the health system.
Venous Thromboembolism
Source: Access Economics, draft Report – Returns to NHMRC funded R&D (2008)
NHMRCNHMRCWorking to build a healthy AustraliaWorking to build a healthy Australia
www.nhmrc.gov.au
• A vaccine against certain types of human papillomavirus.
• Royalties attribution yields a benefit of $63 million per annum to Australia.
• Potential benefits include the saving of 225,000 lives each year worldwide.
• CSL Consolidated Group profit for 2007 = $539.3 million
CSL - Gardasil
Source: Access Economics, draft Report – Returns to NHMRC funded R&D (2008)
